Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 5/20 | 0.42 |
| ▸ | CA9 | Q16790 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA4 | P22748 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | MYC | P01106 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10456207 | 0.90 | ALOX15 (0.47) | ALDH1A1ALOX15SMN1; SMN2LMNAPOLB | |
| SCHEMBL247594 | 0.86 | ALDH1A1 (0.50) | ALDH1A1ALOX15TDP1CA12CA9 | |
| SCHEMBL11180581 | 0.85 | ALDH1A1 (0.48) | ALDH1A1ALOX15TDP1CA12CA9 | |
| SCHEMBL14234964 | 0.85 | ALDH1A1 (0.48) | ALDH1A1ALOX15TDP1CA12CA9 | |
| SCHEMBL27782215 | 0.84 | NR4A3 (0.43) | ALDH1A1ALOX15TDP1CA12CA9 | |
| SCHEMBL3831753 | 0.84 | ALDH1A1 (0.50) | ALDH1A1ALOX15TDP1CA12CA9 | |
| SCHEMBL2228380 | 0.83 | KDM4E (0.44) | ALDH1A1KDM4EHPGDMAPTLMNA | |
| SCHEMBL2574987 | 0.83 | TAAR1 (0.48) | ALDH1A1ALOX15TDP1CA12CA9 | |
| SCHEMBL28284391 | 0.83 | ALDH1A1 (0.46) | ALDH1A1ALOX15TDP1CA12CA9 | |
| SCHEMBL11699226 | 0.82 | ALDH1A1 (0.50) | ALDH1A1ALOX15TDP1CA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158199-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | AstraZeneca AB (SE) | 2010-03-03 | — | — | EP | claimed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | claimed |
| EP-3781574-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | Ascentage Pharma (Suzhou) Co., Ltd. (CN) | 2021-02-24 | — | — | EP | disclosed |
| WO-2020147802-A1 | MACROCYCLIC SPIROETHERS AS MCL-1 INHIBITORS | ASCENTAGE PHARMA (SUZHOU) CO., LTD. (CN) | 2020-07-23 | — | — | WO | disclosed |
| US-9771337-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170088526-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-03-30 | — | — | US | disclosed |
| CN-101679346-B | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI-AVENTIS (FR) | 2014-10-22 | — | — | CN | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | THERAVANCE, INC. (US) | 2012-12-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-7498116-B2 | Resist composition and pattern formation method using the same | FUJIFILM CORPORATION (JP) | 2009-03-03 | — | — | US | disclosed |
| US-7498116-B2 | Resist composition and pattern formation method using the same | FUJIFILM CORPORATION (JP) | 2009-03-03 | — | — | US | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| US-20080241750-A1 | RESIST COMPOSITION AND PATTERN FORMATION METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-10-02 | — | — | US | disclosed |
| US-20080241750-A1 | RESIST COMPOSITION AND PATTERN FORMATION METHOD USING THE SAME | FUJIFILM CORPORATION (JP) | 2008-10-02 | — | — | US | disclosed |
| US-4219570-A | Insect repellents and a method of repelling insects | AJINOMOTO COMPANY, INCORPORATED (JP) | 1980-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120309724-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ALDH1A1 3597/4885ALOX15 4236/4885TDP1 1172/4885 |
| US-20170088526-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | ALDH1A1 3597/4885ALOX15 4236/4885TDP1 1172/4885 |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | CXCR5, CXCR1, CCR5 | ALDH1A1 1892/4885ALOX15 597/4885TDP1 4446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.